News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
AbbVie (ABBV) stock closed up 1.11% in its latest trading session, outperforming the S&P 500 and the Medical sector over the past month. The company is set to release its Q2 earnings on July 31, 2026, with analysts predicting significant growth in EPS and …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%A class action lawsuit has been filed against Abbott Laboratories and its subsidiary Exact Sciences by Illinois patients, alleging the companies failed to adequately protect their sensitive data from a ransomware attack. The breach, for which the cybercriminal group ShinyHunters claimed responsibility, reportedly compromised …
This article from TradingView is a placeholder page for the enterprise value of AbbVie, Inc. (BCS:ABBV0) on the Santiago Stock Exchange. It provides market data, financial links, and community features, but lacks specific valuation data. The page indicates that the market is closed and …
AbbVie (ABBV) stock has shown a counter-cyclical pattern, rising even as the broader market declines, with a low correlation to the S&P 500. This is attributed to its strong business fundamentals, including growth in immunology drugs like Skyrizi and Rinvoq, and recent positive Phase …
Abbott (ABT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares of this maker of infant formula, medical devices …
AbbVie Inc. stock is supported by its 2025 revenue of $56.33 billion and adjusted diluted EPS of $4.85, along with a quarterly dividend of $1.64 per share. The company's 2024 net revenue of $57.0 billion, a 3.7% increase from 2023, provides a strong comparison …
Abbott Laboratories disclosed $1,150,000 in lobbying expenditures for Q2 2026, covering issues such as healthcare legislation, trade agreements, data privacy, and medical device regulations. The report also details recent insider trading activities, congressional stock trades involving ABT, hedge fund adjustments to their holdings, and …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%A gold crown with sparkling dust by tomertu via Shutterstock Choosing the right dividend stock isn't just about chasing the highest yields. The best dividend stocks are often the ones that quietly raise their payouts year after year while continuing to grow the underlying …
Abbott Laboratories is investigating two distinct cybersecurity incidents. One involves the ShinyHunters extortion gang claiming a breach of internal legacy systems in its Cancer Diagnostics business, potentially exfiltrating sensitive customer and medical data. The second incident concerns a threat actor named ShadowByt3$ claiming to …
Abbott Laboratories is investigating two separate cyber incidents, one affecting its Cancer Diagnostics business and another involving its LabCentral customer portal. While Abbott asserts no impact on manufacturing or patient care and denies sensitive customer data exposure through LabCentral, cybercriminal groups ShinyHunters and ShadowByt3$ …
AbbVie's Allergan has received European approval for its new "Botox-lite" treatment. This development marks a significant step for Allergan in expanding its cosmetic product offerings within the European market. The article is from Crain's Chicago Business, indicating local relevance for the company's operations.
AbbVie Inc. (ABBV) continues to attract investor attention with its robust revenue growth of 12.40% and a market capitalization of $449.63 billion. While its dividend yield of 2.72% is appealing, its high payout ratio of 325.98% warrants careful monitoring. Analysts remain largely positive, with …
Abbott Laboratories is investigating two cybersecurity incidents: one involving the ShinyHunters group compromising legacy Exact Sciences systems and exfiltrating data via a vishing campaign, and another focusing on the LabCentral customer portal, with ShadowByt3$ claiming to have stolen technical documentation. While ShinyHunters threatened public …
Abbott Laboratories (ABT) recently reported Q2 2026 earnings with robust revenue growth but a significant drop in net profit margins from 32.4% to 11.6%. While consensus forecasts anticipate higher profit margins and 16.7% annual earnings growth, the current lower margin base and 7.9% trailing …
Sharemaestro market context Price above Trend Line 52 weeks -1.0% · Next-week setup positive 57.3%Abbott Laboratories is investigating two distinct cyber incidents involving unauthorized access to internal systems at its cancer diagnostics business and its LabCentral portal. The company stated that no operations were affected, no other businesses or systems were impacted, and there was no known exposure …
Sharemaestro market context Price above Trend Line 52 weeks -14.8% · Next-week setup positive 55.5%Abbott Laboratories is investigating two separate cybersecurity incidents. One involves the ShinyHunters extortion group, which claims to have stolen data from Abbott's Cancer Diagnostics business systems through a vishing attack. The second incident involves the threat actor ShadowByt3$, who claims to have breached Abbott's …
AbbVie's Allergan Aesthetics has received European Commission approval for Boey (trenibotulinumtoxinE), a new rapid-onset neurotoxin for treating frown lines. This product aims to expand AbbVie's aesthetics portfolio in Europe by offering patients faster visible effects and more flexible treatment schedules. Investors are encouraged to …
Sharemaestro market context Trend signal active 52 weeks +40.4% · Next-week setup negative 42.8%Abbott has disclosed a cyberattack impacting a limited number of internal systems within its cancer diagnostics business. The company confirmed that other Abbott businesses, sites, or systems were not affected, and there was no impact on operations, products, or patient services. An investigation is …
Abbott Laboratories reported strong second-quarter results, surpassing analyst expectations for both adjusted earnings and revenue, and subsequently raised its full-year adjusted earnings guidance. Following this positive news, analysts from BTIG and Evercore ISI Group increased their price targets for Abbott stock, while RBC Capital …
Abbott Laboratories (ABT) stock has fallen 23% this year but management forecasts a significant second-half growth acceleration, raising its full-year profit outlook. Investors are faced with the challenge of betting on this predicted surge, relying on a turnaround in various divisions and successful new …
Abbott Laboratories (NYSE:ABT) exceeded Wall Street's revenue and adjusted EPS expectations in Q2 CY2026, with sales up 13% year-on-year to $12.59 billion and non-GAAP profit reaching $1.31 per share. Despite a decrease in operating margin, the company's management raised its full-year Adjusted EPS guidance. …
Abbott (NYSE: ABT) announced its second-quarter 2026 financial results, reporting substantial growth and raising its full-year EPS guidance. The company achieved 13.0 percent reported sales growth and 4.8 percent comparable sales growth, with GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31. …
Abbott Laboratories' Q2 earnings report has reassured Wall Street, demonstrating that its integration of Exact Sciences is progressing better than anticipated, leading to solid growth and improved profitability metrics. The company reported 13% growth and 4.8% organic growth, exceeding adjusted EPS forecasts and prompting …
Sharemaestro market context Price above Trend Line 52 weeks -18.1%Several major stocks, including Abbott Laboratories, AtaiBeckley, and ManpowerGroup, saw significant gains on Thursday. Abbott Laboratories shares jumped after reporting better-than-expected quarterly results and raising its FY26 EPS guidance. AtaiBeckley surged following an acquisition announcement by Lilly, while ManpowerGroup also rose due to strong …
Abbott is expected to launch several new medical devices, signaling the company's return to relying on innovative products across its divisions as market conditions normalize post-pandemic. The article, authored by Debbie S. Wang, also referenced strong second-quarter earnings that eased jitters from a softer …
Healthcare sector analysts have issued bullish sentiments on Fractyl Health, Inc. (GUTS) and AbbVie (ABBV). H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating for Fractyl Health with an $8.00 price target, while William Blair analyst Matt Phipps maintained a Buy rating for AbbVie. …
Abbott Laboratories' stock saw its best day in 24 years, leading the S&P 500 after reporting better-than-expected earnings for its second quarter. The company also raised its full-year profit outlook, driven by improved sales in its nutrition segment.
AbbVie Inc. is navigating a transitional period marked by the decline of its flagship drug Humira due to biosimilar competition, balanced by the growth of its newer immunology and neuroscience treatments. Investors are focusing on the pace at which these new therapies can offset …
AbbVie (ABBV) is set to report its second-quarter 2026 results, with investor attention on its neuroscience portfolio following a 26% revenue increase in Q1. The Zacks Consensus Estimate predicts 15% year-over-year growth for neuroscience revenues, driven by drugs like Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, …
Abbott Laboratories (NYSE:ABT) saw its shares rise by nearly 11% after reporting strong second-quarter 2026 results that surpassed Wall Street expectations, with adjusted diluted EPS of $1.31 and revenue of $12.59 billion. The company raised its full-year adjusted diluted EPS guidance to $5.45 to …
Sharemaestro market context Price above Trend Line 52 weeks -18.1%AbbVie (ABBV) stock rose 3.3% today, driven by positive Wall Street sentiment and anticipation of its second-quarter earnings report. Analyst price target increases and new regulatory submissions for drugs like RINVOQ and SKYRIZI indicate strong pipeline momentum, despite ongoing challenges with Humira. Investors are …
AbbVie Inc.'s stock (ABBV) rose by 3.32% due to positive clinical trial outcomes for Skyrizi and Rinvoq, reinforcing its post-Humira growth strategy. Institutional investors are favoring healthcare stocks like AbbVie for its dividend profile and resilient cash flow, amidst a broader market shift from …
Abbott stock surged to a three-month high after the company raised its full-year earnings outlook for 2026. This positive revision follows a strong second-quarter report. The new guidance indicates an adjusted earnings per share of $5.45 to $5.60, an increase of about 4 cents …
Search by ticker symbol or company name and select a result to open its chart.